This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Gingival hypertrophy secondary to phenytoin

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Gingival overgrowth occurs in roughly half of the patients taking phenytoin. Changes are most severe in the first year of treatment but can resolve if the drug is withdrawn. Poor oral hygiene exacerbates the effect.

It is hypothesised that plaque causes inflammation with an increased turnover of connective tissue, phenytoin inhibits cellular folate uptake and the folate-depleted cells cannot enzymes to break down the excess of connective tissue.

Management entails:

  • scrupulous oral hygiene:
    • counsel the patient beforehand about the requirement for regular and thorough brushing
    • chlorhexidine mouthwash may be used prophylactically
  • oral folic acid has been found to decrease the incidence of phenytoin induced gingival overgrowth in children on phenytoin monotherapy
  • treat established overgrowth:
    • surgical excision until aesthetic improvement
    • change of anticonvulsant if overgrowth is severe and persistent

Reference:

  • Seymour, R.A.. Phenytoin and gingival overgrowth. Prescribers' Journal 1992;32(3): 124-126.
  • Arya R et al. Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children.Neurology. 2011 Apr 12;76(15):1338-43.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.